Avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients with high-expression PD-L1+ metastatic non-small cell lung cancer: primary analysis from the phase 3 JAVELIN Lung 100 trial.

Fiche publication

Date publication

septembre 2023

Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie

Tous les auteurs :
Reck M, Barlesi F, Chih-Hsin Yang J, Westeel V, Felip E, Özgüroğlu M, Cobo Dols M, Sullivan R, Kowalski DM, Andric Z, Ho Lee D, Sezer A, Hu P, Wang X, von Heydebreck A, Jacob N, Tadjalli Mehr K, Park K

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37748693

Résumé

We report the primary analysis from JAVELIN Lung 100, a phase 3 trial comparing avelumab (anti⁠-PD-L1) vs platinum-based doublet chemotherapy as first-line treatment for PD-L1+ advanced non-small cell lung cancer (NSCLC).